Solaris Resources Inc. (CVE:SLS – Free Report) – Research analysts at HC Wainwright boosted their FY2026 earnings estimates for Solaris Resources in a note issued to investors on Monday, April 13th. HC Wainwright analyst H. Ihle now forecasts that the company will post earnings of ($0.47) per share for the year, up from their prior estimate of ($0.48).
Solaris Resources Stock Down 2.7%
Shares of SLS stock opened at C$6.15 on Wednesday. The business’s fifty day simple moving average is C$6.15 and its 200-day simple moving average is C$6.15. Solaris Resources has a 12-month low of C$1.38 and a 12-month high of C$7.09.
About Solaris Resources
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer.
Read More
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
